MedPath

Raziel Therapeutics (RT) Ltd

🇮🇱Israel
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:0
Completed:9

Trial Phases

2 Phases

Phase 1:2
Phase 2:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2
7 (77.8%)
Phase 1
2 (22.2%)

An Open-label Study That Will Test a Second Treatment Session of RZL-012.

Phase 2
Completed
Conditions
Submental Fat
Interventions
First Posted Date
2023-03-10
Last Posted Date
2023-11-18
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
15
Registration Number
NCT05763160
Locations
🇺🇸

Luxurgery, Manhattan, New York, United States

Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

Phase 1
Completed
Conditions
Submental Fat
Interventions
Drug: RZL-012+Lidacaine injection prior treatment
Drug: RZL-012+Medrol
Drug: RZL-012+Celecoxib+Zyrtec
Drug: RZL-012+facial and neck wrap
First Posted Date
2022-07-27
Last Posted Date
2024-01-30
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
48
Registration Number
NCT05476679
Locations
🇺🇸

Luxurgery, Manhattan, New York, United States

An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.

Phase 1
Completed
Conditions
Submental Fat
Interventions
First Posted Date
2022-07-20
Last Posted Date
2023-12-19
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
20
Registration Number
NCT05466448
Locations
🇺🇸

Luxurgery, New York, New York, United States

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

Phase 2
Completed
Conditions
Flank Mass
Interventions
Drug: Placebo
First Posted Date
2022-07-06
Last Posted Date
2023-11-18
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
12
Registration Number
NCT05445557
Locations
🇺🇸

Luxurgery, New York, New York, United States

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Phase 2
Completed
Conditions
Submental Fat
Interventions
Drug: Placebo
First Posted Date
2021-04-30
Last Posted Date
2023-09-28
Lead Sponsor
Raziel Therapeutics Ltd.
Target Recruit Count
151
Registration Number
NCT04867434
Locations
🇺🇸

DenovaResearch, Chicago, Illinois, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.